Clinical Trials Directory

Trials / Completed

CompletedNCT01818583

Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
143 (actual)
Sponsor
Diakonhjemmet Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Atrial fibrillation is a condition in which the heart's upper chambers, the atria, contract at an abnormally rapid rate. It is a common type of arrhythmia, and occurs in 1-2% of the general population. The prevalence of atrial fibrillation increases with age. Between 50 and 70% of patients with atrial fibrillation lasting \<48 hours spontaneously convert to normal sinus rhythm, and drug therapy increases the likelihood of conversion to sinus rhythm. Another treatment option for conversion of atrial fibrillation and atrial flutter is electrical conversion. This is an effective treatment but requires anesthesia. Current treatment strategy for medical conversion of atrial fibrillation and atrial flutter is to employ drugs that affect ion channel activity in atrial cardiomyocytes. However, such converting drugs all have potentially serious side effects and are expensive. Potassium, sodium, calcium, and magnesium molecules are the most important ions causing electric current in the heart tissue. Our hypothesis is that hypokalemia promotes atrial fibrillation/atrial flutter by a direct effect on cardiomyocytes. Accordingly, we also hypothesize that potassium infusion may convert atrial fibrillation/atrial flutter to normal sinus rhythm. If so, this would be an inexpensive treatment with potentially very few side effects.

Conditions

Interventions

TypeNameDescription
DRUGPotassium chloride
DRUGGlucose 50 MG/ML

Timeline

Start date
2013-03-01
Primary completion
2017-11-01
Completion
2017-11-01
First posted
2013-03-26
Last updated
2018-07-31

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT01818583. Inclusion in this directory is not an endorsement.